The Latest Breaking News from biotechnology

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

Ark ETFs bought and sold biotechnology stocks. Ark's flagship fund trails the S&P 500 over the past five years.

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb).  The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

The former owner of two Vermont ski resorts is facing sentencing for his role in a failed plan to build a biotechnology plant in Vermont using tens of millions of dollars in foreign investors’ money raised through a special visa program that was part of the largest fraud case in…

Secretary of Department of Biotechnology Rajesh S Gokhale on Friday was given additional charge of the post of Director-General, Council of Scientific and Industrial Research (CSIR)-cum-Secretary, Department of Scientific and Industrial Research. Full story on Dynamite News:

The film that took Akshun Abhi, all of 24 years, and the team of 7 Rounds to Cannes is based on last year’s Kansas racial killing in which a 51-year-old Navy veteran shot an Indian techie who was enjoying a drink with a friend in a pub.“Suddenly, this man walked…